ABSTRACT
Thrombin inhibitors share certain properties. They raise both the INR and aPTT since thrombin is part o f the common pathway of blood coagulation. Clinically they are monitored by the aPTT, usually aiming for a goal of 2-2.5 times normal control. More precise monitoring can be achieved by using the ecarin time. No effective antidote exists for these agents.
